EA019206B1 - Пиразиновые соединения в качестве ингибиторов фосфодиэстеразы 10 - Google Patents

Пиразиновые соединения в качестве ингибиторов фосфодиэстеразы 10 Download PDF

Info

Publication number
EA019206B1
EA019206B1 EA201100748A EA201100748A EA019206B1 EA 019206 B1 EA019206 B1 EA 019206B1 EA 201100748 A EA201100748 A EA 201100748A EA 201100748 A EA201100748 A EA 201100748A EA 019206 B1 EA019206 B1 EA 019206B1
Authority
EA
Eurasian Patent Office
Prior art keywords
benzo
pyrazin
phenyl
yloxy
imidazol
Prior art date
Application number
EA201100748A
Other languages
English (en)
Russian (ru)
Other versions
EA201100748A1 (ru
Inventor
Дженнифер Р. Аллен
Мэтью П. Борбо
Нинг Чен
Эсса Ху
Роксан Кунц
Шэннон Румфельт
Original Assignee
Амген Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Амген Инк. filed Critical Амген Инк.
Publication of EA201100748A1 publication Critical patent/EA201100748A1/ru
Publication of EA019206B1 publication Critical patent/EA019206B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA201100748A 2008-11-14 2009-11-16 Пиразиновые соединения в качестве ингибиторов фосфодиэстеразы 10 EA019206B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11456708P 2008-11-14 2008-11-14
US16621209P 2009-04-02 2009-04-02
PCT/US2009/064637 WO2010057121A1 (en) 2008-11-14 2009-11-16 Pyrazine compounds as phosphodiesterase 10 inhibitors

Publications (2)

Publication Number Publication Date
EA201100748A1 EA201100748A1 (ru) 2011-10-31
EA019206B1 true EA019206B1 (ru) 2014-01-30

Family

ID=41478512

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201100748A EA019206B1 (ru) 2008-11-14 2009-11-16 Пиразиновые соединения в качестве ингибиторов фосфодиэстеразы 10

Country Status (30)

Country Link
US (4) US8053438B2 (enExample)
EP (1) EP2364308B1 (enExample)
JP (1) JP5746972B2 (enExample)
KR (1) KR20110083746A (enExample)
CN (1) CN102300860B (enExample)
AR (1) AR074358A1 (enExample)
AU (1) AU2009313768B2 (enExample)
BR (1) BRPI0922095A2 (enExample)
CA (1) CA2742993C (enExample)
CL (1) CL2011001094A1 (enExample)
CO (1) CO6382157A2 (enExample)
CR (1) CR20110326A (enExample)
CY (1) CY1113680T1 (enExample)
DK (1) DK2364308T3 (enExample)
EA (1) EA019206B1 (enExample)
ES (1) ES2397218T3 (enExample)
HR (1) HRP20130054T1 (enExample)
IL (1) IL212687A0 (enExample)
MA (1) MA32889B1 (enExample)
MX (1) MX2011005100A (enExample)
NZ (1) NZ592508A (enExample)
PE (1) PE20110581A1 (enExample)
PL (1) PL2364308T3 (enExample)
PT (1) PT2364308E (enExample)
RS (1) RS52598B (enExample)
SI (1) SI2364308T1 (enExample)
SM (1) SMT201200061B (enExample)
TN (1) TN2011000221A1 (enExample)
TW (1) TWI396689B (enExample)
WO (1) WO2010057121A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2632900C2 (ru) * 2010-11-19 2017-10-11 Лиганд Фармасьютикалс Инкорпорейтед Гетероциклические амины и их применение

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
CA2746307C (en) * 2008-12-17 2013-11-19 Amgen Inc. Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors
BRPI1008498B8 (pt) 2009-02-05 2021-05-25 Takeda Pharmaceuticals Co compostos de piridazinona úteis como inibidores da fosfodiesterase 10a, composição farmacêutica, e, uso de um composto
JP5739415B2 (ja) 2009-05-12 2015-06-24 ブリストル−マイヤーズ スクウィブ カンパニー （Ｓ）−７−（［１，２，４］トリアゾロ［１，５−ａ］ピリジン−６−イル）−４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロイソキノリンの結晶形態およびその使用
CN102595902B (zh) * 2009-05-12 2015-04-29 阿尔巴尼分子研究公司 7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉及其用途
AU2011217206A1 (en) 2010-02-19 2012-08-02 Boehringer Ingelheim International Gmbh Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
AU2011270994B2 (en) 2010-06-24 2015-12-10 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds as phosphodiesterases (PDES) inhibitors
JP5760085B2 (ja) * 2010-08-04 2015-08-05 武田薬品工業株式会社 縮合複素環化合物
EP2602255B1 (en) 2010-08-04 2017-04-26 Takeda Pharmaceutical Company Limited Fused heterocyclic ring compound
US9150588B2 (en) 2010-08-10 2015-10-06 Takeda Pharmaceutical Company Limited Substituted pyridazin-4(1H)-ones as phosphodiesterase 10A inhibitors
JP6106603B2 (ja) 2011-01-11 2017-04-05 スノビオン プハルマセウトイカルス インコーポレイテッド ヘテロアリール化合物及びその使用方法
EP2687529B1 (en) * 2011-03-16 2016-07-13 Takeda Pharmaceutical Company Limited Condensed heterocyclic compound
TWI570122B (zh) 2011-06-22 2017-02-11 武田藥品工業股份有限公司 稠合雜環化合物之結晶
EP2890370B1 (en) * 2012-08-31 2019-10-09 The Regents of the University of California Agents useful for treating obesity, diabetes and related disorders
CN102911135B (zh) * 2012-10-18 2016-01-13 内蒙古工业大学 2-巯基苯并噻唑类衍生物的合成方法
PE20151301A1 (es) 2013-02-05 2015-09-16 Purdue Pharma Lp Formulaciones farmaceuticas resistentes a la manipulacion indebida
EP2975037A4 (en) 2013-03-15 2016-08-10 Daiichi Sankyo Co Ltd benzothiophene derivative
US10039764B2 (en) 2013-07-12 2018-08-07 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression
EP3049086A4 (en) 2013-09-27 2017-02-22 Nimbus Iris, Inc. Irak inhibitors and uses thereof
US9657015B2 (en) 2014-07-31 2017-05-23 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
CN104649882A (zh) * 2015-02-11 2015-05-27 南通恒盛精细化工有限公司 一种磷酸二酯酶抑制剂的中间体制备工艺
US10807983B2 (en) 2015-03-16 2020-10-20 Ligand Pharmaceuticals, Inc. Imidazo-fused heterocycles and uses thereof
WO2017047602A1 (ja) * 2015-09-18 2017-03-23 科研製薬株式会社 ビアリール誘導体及びそれを含有する医薬
CN112979661B (zh) * 2018-01-19 2022-05-17 苏州信诺维医药科技股份有限公司 杂环化合物、制备方法及其在医药上的应用
CN109020977B (zh) * 2018-10-26 2020-11-13 安庆奇创药业有限公司 一种Acalabrutinib的制备方法
US12359128B2 (en) 2020-12-17 2025-07-15 Merck Patent Gmbh Heteroaromatic isothiocyanates
CN113929598A (zh) * 2021-11-24 2022-01-14 上海吉奉生物科技有限公司 一种（s）-2-叔丁氧羰基氨基-3-（4,4-二氟环己基）丙酸的合成方法
TWI878871B (zh) * 2022-05-09 2025-04-01 大陸商浙江同源康醫藥股份有限公司 多環類化合物及其用途
CN115894181A (zh) * 2022-09-30 2023-04-04 渭南高新区海泰新型电子材料有限责任公司 一种环己烯基环己基二氟苯类液晶化合物的合成方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007098169A1 (en) * 2006-02-21 2007-08-30 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors
WO2007129183A2 (en) * 2006-05-02 2007-11-15 Pfizer Products Inc. Bicyclic heteroaryl compounds as pde10 inhibitors
WO2008084299A1 (en) * 2006-12-21 2008-07-17 Pfizer Products Inc. Succinate salt of 2-((4-(1-methyl-4-(pyridin-4-yl)-1h-pyrazol-3-yl) phenoxy)methyl)quinoline

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4198417A (en) 1979-01-10 1980-04-15 American Hoechst Corporation Phenoxyphenylpiperidines
BRPI0408320A (pt) 2003-04-04 2006-03-07 Lundbeck & Co As H composto, composição farmacêutica, uso de um composto, e, método para o tratamento de um distúrbio afetivo
DE10337942A1 (de) 2003-08-18 2005-03-17 Merck Patent Gmbh Aminobenzimidazolderivate
DE10344223A1 (de) 2003-09-24 2005-04-21 Merck Patent Gmbh 1,3-Benzoxazolylderivate als Kinase-Inhibitoren
DE10349587A1 (de) 2003-10-24 2005-05-25 Merck Patent Gmbh Benzimidazolylderivate
US7470712B2 (en) 2004-01-21 2008-12-30 Bristol-Myers Squibb Company Amino-benzazoles as P2Y1 receptor inhibitors
ATE531705T1 (de) * 2004-05-18 2011-11-15 Schering Corp Substituierte 2-chinolyloxazole geeignet als pde4 inhibitoren
BRPI0511854A (pt) * 2004-06-07 2008-01-15 Pfizer Prod Inc inibição de fosfodiestearase 10 como tratamento para condições relacionados com a obesidade e relacionadas a sìndrome metabólica
US20060183763A1 (en) * 2004-12-31 2006-08-17 Pfizer Inc Novel pyrrolidyl derivatives of heteroaromatic compounds
DE102005016634A1 (de) 2005-04-12 2006-10-19 Merck Patent Gmbh Neuartige Aza-Hetercyclen als Kinase-Inhibitoren
CA2615890A1 (en) 2005-08-02 2007-02-08 Irm Llc 5-substituted thiazol-2-yl amino compounds and compositions as protein kinase inhibitors
US7868177B2 (en) 2006-02-24 2011-01-11 Amgen Inc. Multi-cyclic compounds and method of use
US20080090834A1 (en) * 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
WO2008057280A1 (en) 2006-10-27 2008-05-15 Amgen Inc. Multi-cyclic compounds and methods of use
EP2215085B1 (en) 2007-10-25 2011-09-07 AstraZeneca AB Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders
WO2009081259A1 (en) 2007-12-21 2009-07-02 Pfizer Inc. Phenoxy-pyridyl derivatives
BRPI0914891A2 (pt) 2008-06-20 2015-11-24 Metabolex Inc agonistas de aril gpr119 e usos dos mesmos

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007098169A1 (en) * 2006-02-21 2007-08-30 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors
WO2007129183A2 (en) * 2006-05-02 2007-11-15 Pfizer Products Inc. Bicyclic heteroaryl compounds as pde10 inhibitors
WO2008084299A1 (en) * 2006-12-21 2008-07-17 Pfizer Products Inc. Succinate salt of 2-((4-(1-methyl-4-(pyridin-4-yl)-1h-pyrazol-3-yl) phenoxy)methyl)quinoline

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2632900C2 (ru) * 2010-11-19 2017-10-11 Лиганд Фармасьютикалс Инкорпорейтед Гетероциклические амины и их применение

Also Published As

Publication number Publication date
WO2010057121A1 (en) 2010-05-20
AR074358A1 (es) 2011-01-12
RS52598B (sr) 2013-04-30
EP2364308B1 (en) 2012-10-24
CN102300860A (zh) 2011-12-28
TW201030006A (en) 2010-08-16
US8053438B2 (en) 2011-11-08
HK1161251A1 (en) 2012-08-24
HRP20130054T1 (hr) 2013-02-28
TWI396689B (zh) 2013-05-21
SI2364308T1 (sl) 2013-01-31
US8247418B2 (en) 2012-08-21
CO6382157A2 (es) 2012-02-15
EA201100748A1 (ru) 2011-10-31
PT2364308E (pt) 2013-01-08
CA2742993C (en) 2015-01-20
IL212687A0 (en) 2011-07-31
US8329700B2 (en) 2012-12-11
PL2364308T3 (pl) 2013-03-29
PE20110581A1 (es) 2011-09-03
US20120277209A1 (en) 2012-11-01
CN102300860B (zh) 2014-08-27
US20110160202A1 (en) 2011-06-30
JP5746972B2 (ja) 2015-07-08
NZ592508A (en) 2013-04-26
AU2009313768B2 (en) 2013-01-10
TN2011000221A1 (en) 2012-12-17
DK2364308T3 (da) 2013-02-04
US20110160182A1 (en) 2011-06-30
MX2011005100A (es) 2011-05-30
KR20110083746A (ko) 2011-07-20
BRPI0922095A2 (pt) 2019-09-24
AU2009313768A1 (en) 2010-05-20
JP2012508776A (ja) 2012-04-12
MA32889B1 (fr) 2011-12-01
CR20110326A (es) 2011-07-28
CY1113680T1 (el) 2016-06-22
CL2011001094A1 (es) 2011-11-11
US20100137278A1 (en) 2010-06-03
EP2364308A1 (en) 2011-09-14
CA2742993A1 (en) 2010-05-20
ES2397218T3 (es) 2013-03-05
SMT201200061B (it) 2013-01-14

Similar Documents

Publication Publication Date Title
JP5746972B2 (ja) ホスホジエステラーゼ１０阻害剤としてのピラジン化合物
EP2364306B1 (en) Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors
US8497265B2 (en) Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors
AU2011253003A1 (en) Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors
JP2013526524A (ja) Ｐｄｅ１０阻害剤としてのアリールおよびヘテロアリール窒素ヘテロ環式化合物
MX2011006575A (es) Compuestos de aminopiridina y carboxipiridina como inhibidores de la fosfodiesterasa 10.
AU2011253058A1 (en) Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors
HK1161251B (en) Pyrazine compounds as phosphodiesterase 10 inhibitors

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): KZ RU